Custom Skin Cancer Shots Stop Tumors From Returning in Landmark Trial
Cambridge, Thursday, 20 August 2026.
Moderna and Merck’s custom mRNA therapy successfully prevented skin cancer recurrence in a landmark final-stage trial, sending Moderna’s stock surging 177% as personalized oncology nears reality.
Landmark Phase 3 Trial Results Announced
On 19 August 2026, pharmaceutical giants Moderna (MRNA) and Merck (MRK) announced positive topline results from the Phase 3 INTerpath-001 trial, evaluating an experimental mRNA cancer vaccine combined with Merck’s immunotherapy drug Keytruda [2][3]. The trial involved 1,137 participants who had undergone surgery to remove high-risk melanoma, specifically targeting stages IIB through IV [2][5]. The combination regimen demonstrated statistically significant and clinically meaningful improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to Keytruda alone [2][5]. This development marks the first Phase 3 study to show that an individualized neoantigen therapy designed based on a patient’s tumor mutational fingerprint can reduce the risk of recurrence or death in this patient population [2][5].
Landmark Phase 3 Trial Results Announced
The investigational vaccine, known as intismeran autogene (mRNA-4157/V940), is designed using the unique set of mutations within each patient’s tumor to activate the immune system [2]. In the trial, patients received intismeran at a dose of 1 mg every three weeks for up to nine doses, totaling a maximum potential administration of 9 mg per patient over the treatment period [2]. Keytruda was administered at 400 mg every six weeks for up to nine cycles [2]. No new safety signals were reported, with safety profiles consistent with previous studies, reinforcing the tolerability of the combination therapy [2][5].
Market Reaction and Financial Impact
Following the announcement, Moderna’s stock price surged approximately 177%, reflecting the market’s valuation of this potential commercial breakthrough [3]. Merck shares also responded positively, rising by more than 12% to reach a market capitalization of approximately $333 billion [3]. Moderna’s market capitalization reached approximately $25 billion following the surge [3]. Analysts had previously noted that these Phase 3 results served as a critical event for Moderna’s stock valuation, with some defining a hazard ratio at or below 0.65 as a clear win for the trial [3][5].
Market Reaction and Financial Impact
The financial implications extend beyond immediate stock performance, signaling a potential shift in the oncology treatment landscape. Previous Phase 2b data from the KEYNOTE-942 trial had shown the combination reduced the risk of recurrence or death by 49% compared to Keytruda alone [2]. The successful completion of Phase 3 endpoints validates the personalized mRNA oncology platform, opening new market opportunities in biotechnology [1][3]. Investors are now weighing the potential revenue streams from a personalized cancer vaccine against the complexities of manufacturing and distribution.
Regulatory Pathway and Future Plans
Moderna and Merck intend to present the full trial details at an upcoming international medical meeting and will engage with regulatory authorities regarding filing submissions [2][5]. Drugmakers plan to initiate regulatory discussions regarding treatment and safety in the next few months, approximately between September and November 2026 [3]. The study will continue to evaluate additional endpoints, including overall survival (OS), to provide further long-term data on the efficacy of the treatment [2][5]. This regulatory engagement is a critical step toward potential approval for the adjuvant melanoma setting.
Regulatory Pathway and Future Plans
The broader clinical development program, INTerpath, encompasses nine Phase 2 and Phase 3 trials across various cancers, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma [2][3]. This expansion indicates a strategic pivot towards leveraging mRNA technology for solid tumors beyond melanoma [3][5]. Company executives described the results as a pivotal moment for cancer research, transitioning the concept of personalized mRNA treatment from aspirational to reality [2][5]. The outcome of regulatory discussions in late 2026 will determine the timeline for patient access to this new therapy.
Clinical Context and Safety Profile
Keytruda, the immunotherapy drug used in combination, is associated with immune-mediated adverse reactions, with previous studies showing permanent discontinuation rates ranging from 8% to 31% depending on the trial and combination [2]. In the INTerpath-001 trial, the safety profile remained consistent with previous studies, with no new signals identified [2][5]. Specific adverse reactions associated with Keytruda monotherapy in other contexts include fatigue, nausea, and immune-mediated conditions such as pneumonitis and colitis [2]. Monitoring for these reactions remains a standard part of the treatment protocol for patients receiving the combination therapy.
Clinical Context and Safety Profile
The success of this trial builds upon a decade of melanoma clinical trials aimed at improving long-term outcomes for patients [2]. In 2022, there were over 330,000 new melanoma cases diagnosed worldwide, with the U.S. estimated to have approximately 112,000 new cases in 2026 [2]. The availability of a personalized vaccine could significantly alter the treatment paradigm for high-risk patients who have undergone surgical resection [2][5]. Continued monitoring of overall survival data will be essential to confirm the long-term benefits observed in recurrence-free survival metrics.